Lives unaffected by cystic fibrosis

Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherRecruiting Location: Australia

    A Phase 2 Study to evaluate the safety, tolerability, PK and PD in cystic fibrosis patients with at least 1 G542X Allele , protocol number ELX-02 NCT04126473

    This is a Phase 2 open label study to evaluate the safety, tolerability, PK and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allelle.

    • Age:

      16 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalRecruiting Location: Alfred Hospital, Victoria

    Modified Release Posaconazole in patients with cystic fibrosis , protocol number NCT03421366

    A prospective single centre observational cohort of patients with cystic fibrosis to determine whether adequate serum levels of posaconazole, after administration of the newer modified release once daily oral formation, can be achieved.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part B) , protocol number NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      Less than 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      2 Years

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A) , protocol number NCT04509050

    This two part study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 4 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Australia

    A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in subjects with cystic fibrosis who are less than 24 months of age and have an Ivacaftor-Responsive CFTR Mutation , protocol number NCT02725567

    The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation

    • Age:

      Maximum 24 months of Age

    • Mutation(s):

      One copy F508del

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • OtherRecruiting Location: Queensland Children's Hospital & The Children's Hospital Westmead

    A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in subject 6 through 11 years of Age with cystic fibrosis and F/MF genotypes , protocol number NCT04353817

    This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

    • Age:

      6 Years through to 11 Years

    • Mutation(s):

      Two copies of F508del

    • FEV1% Predicted:

      70%

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple care centres across the US

    Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN) , protocol number BEGIN NCT04509050

    This two-part observational study will look at the effects of CFTR modulators on growth in infants and young children with CF. These drugs are intended to help CFTR protein function closer to normal.

    • Age:

      0 Years to 6 Years

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      No FEV1 Limit

    • Number of Visits:

      6

    • Length of Participation:

      3 Years

    Contact us about this clinical Trial >
  • Mucociliary ClearanceEnrolling Location: Australia & New Zealand

    Study to evaluate ARO-ENaC in adults with cystic fibrosis (AROENaC-1001) , protocol number ARO-ENaC NCT04375514

    This study will evaluate the safety and tolerability of ARO-ENaC, a drug intended to thin airway surface liquid. Multiple doses of the drug will be tested in adults with cystic fibrosis to find the optimal dose.

    • Age:

      18 Years to 55 Years

    • Mutation(s):

      No mutation requirements

    • FEV1% Predicted:

      between 40% and 99%

    • Number of Visits:

      12

    • Length of Participation:

      113 days

    Contact us about this clinical Trial >
  • Anti-InflammatoryNot yet recruiting Location: Brisbane

    A double blind, randomized, placebo controlled, cross-over trial investigating the effect of High Amylose Maize Starch (HAMS) supplementation on fecal microbiological and inflammatory outcomes in individuals with Cystic Fibrosis and Healthy Volunteers , protocol number ACTRN12618000283279

    Cystic Fibrosis (CF) is associated with a significant increase in gut dysbiosis. Exposure to multiple courses of antibiotics as well as an inherently inflammatory gut contributes to this. We have shown that there are significant differences between the CF gut and healthy volunteers in these respects. High amylose maize starch (HAMS) is a pre-biotic food stuff produced in such a way as to encourage the production of beneficial, anti-inflammatory compounds. In laboratory culture, we have shown that HAMS increases the production of these compounds. What is not clear however is whether this laboratory data translates to a clinical benefit. This study will attempt to understand the impact of HAMS supplementation on the bacteria in the gut and the ability of the gut to make anti-inflammatory compounds, in adult patients with CF as well as in healthy control subjects.

    • Age:

      18 Years and Older

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not specified

    Contact us about this clinical Trial >
  • Nutritional-GIEnrolling Location: Ohio, USA

    OPTION 2: Study of AzurRX MS1819 in enteric capsules in adults with cystic fibrosis and exocrine pancreatic insufficiency (AzurRX AZ-CF2002) , protocol number NCT04375878

    This study will look at the safety and effectiveness of the drug MS1819 in enteric capsules as a pancreatic enzyme replacement therapy (PERT).

    • Age:

      18 Years and Older

    • Mutation(s):

      No Mutation Requirement

    • FEV1% Predicted:

      30% or greater

    • Number of Visits:

      10

    • Length of Participation:

      8 weeks

    Contact us about this clinical Trial >
  • Displaying results 31-40 (of 231)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|